Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC

Conditions: Hepatocellular Carcinoma Non-resectable Interventions: Drug: Sin-Bev-SIRT Sponsors: Second Affiliated Hospital of Guangzhou Medical University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials